Physician profile
Michael J Lambo
NPI 1932107893
$6,170.55
in general payments reported to CMS, 2019-2025
32 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.58 · 2020: $57.64 · 2021: $296 · 2022: $779 · 2023: $1,465 · 2024: $1,911 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,013.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,001.43 | 2022-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $729.34 | 2022-2025 | |
| Bioprotect Medical, INC. | $551.28 | 2024-2025 | Bioprotect Balloon Implant System |
| Sumitomo Pharma America, INC. | $416.05 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $311.42 | 2023-2025 | |
| Tolmar, INC. | $293.61 | 2023-2025 | Eligard, Jatenzo |
| Progenics Pharmaceuticals, INC. | $283.21 | 2023-2025 | Pylarify |
| Myriad Genetic Laboratories, INC. | $274.21 | 2022-2023 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $247.02 | 2019-2025 | Lynparza |
| Boston Scientific Corporation | $213.30 | 2020-2022 | |
| Astellas Pharma US INC | $201.57 | 2023-2025 | Xtandi |
| Novartis Pharmaceuticals Corporation | $188.85 | 2024-2025 | |
| Astellas Pharma Global Development | $171.30 | 2024 | Xtandi |
| Immunitybio, INC. | $168.58 | 2025 | |
| Blue Earth Diagnostics | $148.24 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $127.09 | 2023-2025 | Illuccix |
| Myovant Sciences INC. | $125.39 | 2022 | |
| Teleflex LLC | $122.64 | 2022-2025 | Urolift |
| Merck Sharp & Dohme LLC | $98.50 | 2024-2025 | Keytruda, Welireg |
| Palette Life Sciences, INC. | $89.61 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $75.05 | 2023-2024 | Provenge |
| Urogen Pharma, INC. | $66.88 | 2022-2025 | Jelmyto |
| Axonics, INC. | $42.11 | 2022 | |
| Bluewind Medical | $36.13 | 2024 | Revi |
| Procept Biorobotics Corporation | $33.89 | 2022-2024 | Aquabeam System |
| Laborie Medical Technologies Corp. | $32.44 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Sun Pharmaceutical Industries INC. | $26.26 | 2023 | Odomzo, Yonsa |
| Olympus America INC. | $24.45 | 2025 | Itind System |
| Foundation Medicine, INC. | $22.47 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $21.40 | 2022 | |
| Verity Pharmaceuticals INC. | $16.12 | 2025 | Trelstar |
| Optovue, INC. | $10.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lambo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.